Novel 2,5-Diazabicyclo[4.2.0]octanes as GLP-1 Receptor Modulators for Treating Type 2 Diabetes.

Published in: ACS medicinal chemistry letters (2023)

Provided herein are 2,5-diazabicyclo[4.2.0]octanes as GLP-1 receptor modulators, pharmaceutical compositions, use of such compounds in treating type 2 diabetes, and processes for preparing such compounds.

Keyphrases

type diabetes
small molecule

glycemic control
cardiovascular disease

insulin resistance
binding protein

adipose tissue
skeletal muscle